We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


26 Apr 2006 By Robert Cyran

Executive pay in the US may be as oversized as the food portions, but investors have been reluctant to tackle abuses. But two battles at Pfizer and UnitedHealth show how difficult it will be to reign in excess pay.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)